Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.

+ Publication-Date Published in the last:

30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years

Or published in the following date range:
From (yyyy/mm/dd - month and day are optional) to ('to' is optional)
+ Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+ Sort-Order
Sort the retrieved articles by:
relevance
publication date
+ Language And with languages:

+ Species
And for:
Humans
Animals
+ Gender
And for:
Male
Female
+ Age And for these age groups:

Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years

+ Title
And for this query matching the titles:
+ Transliterated-Title
And for this query matching the title in original language:
+ Abstract
And for this query matching the abstratcs:
+ Major-Mesh
And for this query matching the MeSH-Major terms:
+ Mesh
And for this query matching any MeSH terms:
+ Journal
And for one or more of these journal abbreviated names:
OR OR
(see title abbreviations)+ Volume
And with journal volume number:
+ Issue
And with journal issue number:
+ Page
And with page number:
+ ISSN
And with ISSN:
+ Publication-Place
And with journal's country of publication:
+ Author

+ Affiliation
And with affiliation to:
+ Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior) + PMID
Show me only articles for these PMIDs (PubMed IDs):

Page Format
Any submit button will submit all of the items you have changed.

[Title] [Nephromegaly: as unusual presentation of acutelymphoblasticleukemia in an infant].

Nephromegaly in infancy may be due to several causes, being the most relevant: renal polycystic autosomic recessive disease, venous renal thrombosis, deposit diseases, kidney tumors, nephrotic congenital syndrome and neoplastic infiltration.

Although renal infiltration is relatively frequent in acutelymphoblasticleukemia, nephromegaly is an unusual form of presentation in this pathology.

(PMID = 28080695.001).

[ISSN] 2047-9018

[ISO-abbreviation] Nurs Stand

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

11. Pay cut after 'best year'?Nurs Stand; 2006 Nov 01;21(8):1

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pay cut after 'best year'?

: When governments boast about how well the health service is performing under their stewardship - usually the number of patients treated and how quickly - they are really describing the achievements of staff in hospitals and the community.

After all, no minister has ever actually walked into a treatment centre or a patient's home and delivered care themselves.

[Email]Email this result itemEmail the results to the following email address: [X] Close

[Publication-type] Journal Article

[Publication-country] United States

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In this paper, we compare seasonal variation in death rates for terminally ill cancer patients to terminally ill patients who are "frail," i.e., those with neurodegenerative disease, general debility, or chronic heart failure.

The 72,066 records were analyzed using a three-way analysis of variance (season, place of care, diagnosis) with Bonferroni correction for post-hoc comparisons.

These include a smaller "symptom burden" than frail patients, who frequently have comorbid disease(s) and who are often unable to make their needs known; less compromised immune systems; more aggressive medical treatment; better nutrition; a strong support system (particularly from family and caregivers); and increased sensitivity to factors that may prolong survival, e.g., timely immunizations and even the avoidance of crowds in winter months.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27963828.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Though testing is discouraged in children, prior work suggests they are informed of their tested mothers' mutation status; decisions and outcomes of parental disclosure to children remain largely unknown.

METHODS: We examined predictors of parental disclosure decisions to children ages 8-21 and related outcomes in a large clinical sample (221 tested mothers, 124 untested co-parents).

Parents were interviewed prior to mothers' receipt of BRCA1/2 results and 1 and 6 months later.

RESULTS: 63% of mothers disclosed their results to their children within 1 month of receipt (44% of co-parents also disclosed to children); this increased to 68% by 6 months (55% among co-parents).

Within parenting dyads, mothers were significantly more likely than co-parents to disclose to children in the short-term (X<sup>2</sup>=18.6, p<.0001).

Predictors of maternal disclosure to children included not being a BRCA1/2 mutation carrier, older child age, stronger intentions to disclose, more favorable attitudes toward pediatric BRCA1/2 testing, a more open parent-child communication history, and a decisional balance favoring disclosure (all p's<.05).

When examined simultaneously, mothers who were not mutation carriers (OR=4.02, 95% CI=1.35, 11.94), mothers of older children (OR=1.30, 95% CI=1.13, 1.49), and those with stronger intentions to disclose (OR=1.39, 95% CI=1.10, 1.76) were more likely to communicate.

Other outcomes of maternal disclosure included greater satisfaction with the decision to disclose and more open parent-child communication following disclosure (all p's<.05).

CONCLUSIONS: This is the largest and most well-characterized study on this topic to date.

Short-term rates of parental disclosure to children were high, increasing over time.

Parental disclosure decisions are determined by a complex array of both child and parent factors, with some benefits identified with disclosure.

Findings indicate a need for additional work, including decision support interventions for communication with children.

No significant financial relationships to disclose.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27963706.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Time to leukemia (TTL) was analyzed for each patient sample as time from transplant to overt leukemia in the recipients.

METHODS: Gene expression profiles of ALL samples (N = 14) with short versus long TTL in the xenograft model were analyzed using a human whole genome array (Affymetrix U133 Plus 2.0) correlating gene expression values (relative expression) to the time from transplant to manifestation of leukemia in the NOD/SCID mice (TTL, in weeks) by quantitative traits analysis (QTA).

Patient samples exhibiting a short time to overt leukemia in the xenotransplant model associated with poor relapse free survival showed down-regulated XAF1 and impaired caspase-3 activation leading to decreased apoptosis of the leukemia cells.

CONCLUSIONS: Taken together, we used a novel approach directly correlating gene expression values to time from transplant to overt leukemia (TTL) identifying the apoptosis regulator XAF1 to be associated with poor outcome of patients.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27962468.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: e14623 Background: Notch signaling is an evolutionary-conserved pathway in vertebrates and invertebrates which is involved many developmental processes, including cell fate decisions, apoptosis, proliferation, and stem-cell self renewal.

Increasing evidence suggests that the Notch signaling pathway is frequently up regulated in many forms of cancer including acute T-cell lymphoblasticleukemia, cervical, prostate, lung, breast and others.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: One hundred and seventy-four consecutive patients (median age 64y, 128 m) underwent both CT and specialist EUS, and the maximum potential tumour cylinder volume (EDTV) was calculated using the formula πr<sup>2</sup>L (cylinder volume), where r = tumour thickness (cm) and L = total length of disease, including the position and level of both the primary tumour and proximal and distal lymph nodes (cm).

Relative risk of patients who has a history of radical nephrectomy for RCC treatment was 4.1 (95% CIs, 1.2 to 13.4), and 5.4 (95% CIs, 1.2 to 27.7) for disease-free survival and disease-specific survival, respectively.

Disease-specific survival of 92% at 5-years and 83% at 10-years is possible.

Preceding radical nephrectomy for RCC treatment was the only independent predicting factor for both disease-free and disease-specific survival.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27964294.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Surgical or endoscopic invasive tube feeding (ITF - gastroscopy/jejunostomy/stent) is a commonly employed strategy to maintain nutritional support however it can cause significant morbidity in its own right.

We sought to determine if a strategy of careful dietary counseling and appropriately-timed neoadjuvant chemotherapy can obviate the need for ITF.

METHODS: Pts undergoing neoadjuvant chemotherapy (TAX/CDDP/5FU Q3 weeks x3) for esophageal or GEJ adenocarcinoma at a single institution from 3/07-7/08 were identified from a prospective database.

All received dietary counseling and were closely monitored for signs/ symptoms of malnutrition with serial (baseline, after 1<sup>st</sup> cycle, pre-surgery) Body Mass Index (BMI), albumin, dysphagia scores (0 best - 4 worse), and quality of life (FACT-E).

We assessed the response of dysphagia and nutritional status to neoadjuvant treatment and the need for ITF.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: 7573 Background: The malignant behavior of small lung adenocarinomas (AD), which have been detected with increasing frequency recently, has not yet been clearly evaluated, and an understanding of this biological characteristic is vital for selecting the appropriate therapeutic strategy.

RESULTS: Examination of tumor aggressiveness based on the presence of lymphatic, vascular and pleural invasion, and of nodal metastasis, showed that maxSUV, BAC ratio, TDR, and GGO ratio, in the order, can reflect the malignancy grade.

MaxSUV and BAC ratio were also valuable prognostic predictors of the disease-free survival.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We reviewed cardiac adverse events in patients with metastatic renal cell carcinoma (RCC) who underwent treatment with this agent.

Among these 17 patients, 12 (70.6%) also experienced left-ventricular systolic (LVEF) dysfunction; in all, 33 of the 175 patients (18.9%) developed some degree of cardiac abnormality, of which 12 were of classified as grade 3 LVEF dysfunction and/or congestive heart failure (CHF) (6.9%).

A significant univariate association for predictors of CHF were history of hypertension (p=0.008), history of coronary heart disease (p=0.0005) and prior treatment with an angiotensin converting enzyme inhibitor (ACE) (p= 0.04).

CONCLUSIONS: Patients undergoing sunitinib, especially those with a previous history of hypertension and coronary heart disease, are at increased risk for cardiovascular events and should be monitored for exacerbations of their hypertension and for evidence of LVEF dysfunction during treatment.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27963002.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Publication-country] United States

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Cause-specific mortality was categorized as death from recurrence/progression of primary disease, external causes, and non-recurrence/non-external causes (Non-Recur/Ext) (i.e., deaths from health conditions including sequelae of cancer therapy).

CONCLUSIONS: All-cause late mortality has improved with more recent eras, attributable to reduced rates of mortality from progression of primary disease (i.e., durable remission).

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27962548.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Association between HER2/neu overexpression and calcifications in breast cancer.

: 579 Background: HER-2/neu overexpression is an important parameter that influences prognosis and treatment for breast cancer.

The purpose of this study is to explore the relationship between HER-2/neu overexpression and calcifications identified by either mammographic imaging or histologic examination.

METHODS: A retrospective review of the prospectively collected database was performed to evaluate the mammographic and histologic characteristics of all cases of invasive breast cancers diagnosed between 2003 and 2008.

HER-2/neu positivity was defined as either overexpression by FISH analysis or 3+ staining on immunohistochemistry.

RESULTS: Of 502 invasive cancers, 165 (33%) had calcifications on mammography and 337 (67%) did not.

HER-2/neu positivity was found in 63 (38%) of the calcification cases and 40 (12%) of the non-calcified cases (p < 0.001).

This association persisted across all age groups and races and was independent of tumor size, nodal status, or hormone receptor status.

Calcifications seen histologically also correlated with HER-2/neu overexpression, but the relationship was more complex.

Among 155 cases with histologic calcifications seen within a ductal intraepithelial neoplasia (DIN) component, there were 45 (29%) that were HER-2/neu positive, compared with 67/414 (16%) that did not have calcifications within DIN (p < 0.001).

If the calcifications were only within invasive tumor, the rate of HER-2/neu overexpression was less, 9/63 (14%).

Multivariate logistic regression showed only the following factors to be significantly associated with HER-2/neu overexpression: grade of invasive tumor, presence of necrosis, progesterone receptor negativity in either the invasive or the in situ component, and mammographic calcifications.

CONCLUSIONS: Recognition of the strong association between HER-2/neu overexpression and mammographic calcifications may have clinical usefulness and could lead to a better understanding of the underlying tumor biology of this important tumor marker.

[Table: see text].

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27960749.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Publication of the French-American-British classification 34 years ago resulted in acceptance that morphology and cytochemistry separated AL into two different diseases, acute myeloid leukemia (AML) and acutelymphoblasticleukemia (ALL), that required separate treatment.

The most striking example of increased curability of AL is acute promyelocytic leukemia, in which targeted therapy combined with chemotherapy has increased survival from a 2-week median to an 80% cure rate.

Among adult de novo AML 40%-45% are cytogenetically normal (CN); the striking molecular heterogeneity of CN-AML is now being recognized and promises to allow individualized approaches that improve substantially upon the current cure rate of 40%.

New approaches to studying the leukemia genome and epigenome should improve our understanding of AL heterogeneity, identify new therapeutic targets, and allow the cure of most patients.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27962366.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: The PPTP includes a molecularly characterized in vitro panel of cell lines (n = 27) and in vivo panel of xenografts (n = 60) representing most of the common types of childhood solid tumors and childhood acutelymphoblasticleukemia (ALL).

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: e15090 Background: The objective was to evaluate the effect of preoperative administration of TACE and chemotherapy on hepatic injury and on postoperative outcome in patients with colorectal liver metastases (CRM) Methods: Seventy seven patients underwent hepatic resection for CRM between January 1999 and December 2007 were evaluated.

Pathologic review of the non-tumorous liver was performed using established criteria for steatosis, steatohepatitis, and sinusoidal dilation.

The effect of two different treatment and hepatotoxicity on postoperative outcome was analyzed.

TACE was associated with steatosis, steatohepatosis and postoperative complication, when compared with no chemotherapy (all p<0.05).Among chemotherapy group,Oxaliplatin was associated with steatohepatitis compared with no preoperative treatment (13.0% v 0%, respectively; p<0.05).

Patients with preoperative chemotherapy had increased steatohepatitis compared with no treatment group (18.5% v 0%, respectively, p=0.0008), the postoperative morbility rate in preoperative chemotherapy (25.9%) was double that of the no-chemotherapy (12.5%), but this difference was not statistically significant (p=0.20).

Preoperative chemotherapy was also not associated with 90-day mortality.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: e14642 Introduction: The ceramides are a major signaling pathway for apoptosis in cells undergoing stress or exposure to chemotherapy.

We have demonstrated synergistic anti-tumor effects of combining C6 ceramide with paclitaxel, doxorubicin and cisplatin and are currently addressing the question; does C6 augment activity of all the major classes of drugs?

Backround: Currently the in vivo anti-tumor effects of C6 with oxaliplatin and Gemcitabine.

Mean survival was increased from 25 to 37 days.

Although short term immunohistochemical studies suggested enhanced apoptosis and increased caspase 3 production by ceramide combinations it may actually be independent of capase activation and mitochondrial activation.

[Publication-country] United States

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Angiogenic biomaker study in osteosarcoma.

: e21507 Background: This study represents a prospective assessment of angiogenesis genes mRNA expression in tumors and blood from patients treated with pre- and post-operative Brazilian osteosarcoma protocol (GCBTO 2006) that introduce metronomic chemotherapy (anti-angiogenic) in order to try to increase survival of osteosarcoma patients.

METHODS: Tumor samples from 27 patients were analyzed before and after chemotherapy to determine VEGFA, VEGFR1, VEGFR2, PDGFC, SDF1 and TSP1 genes expression profile by Quantitative Real Time PCR.

Also, blood samples of these patients were investigated pre- and post-chemotherapy and at the end of high-dose chemotherapy trying to evaluate potential for proangiogenic factors and antiangiogenic factor (TSP1) which could be used to monitor treatment activity.

RESULTS: Of all six genes studied pre- and post- chemotherapy, in tumor samples, only SDF1 and VEGFR2 were underexpressed.

SDF1 gene has the lowest expression at all.

In tumor samples, TSP1 and VEGFA expression was higher than SDF1, VEGFR2 and PDGFC expression in biopsies and surgeries (P=0.001).

VEGFR1 expression was higher than VEGFR2 expression (P=0.001).

PDGFC and VEGFR1 overexpression were associated with necrosis grade I and II (Huvos score) (P=0.005).

VEGFA and TSP1 were overexpressed in 96% and 92% of surgery samples, respectively.

In blood samples from biopsy, surgery and end of treatment there were no statistically significant changes in the marker genes expression.

CONCLUSIONS: The study suggests an association between PDGFC and VEGFR1 overexpression and lower grade necrosis.

TSP1 and VEGFA were the most expressed genes in all tumor samples but TSP1 was lower than VEGFA in biopsies and VEGFA was lower than TSP1 in surgery (P=0.001).

Although VEGFR2 is the primary receptor of VEGF, VEGFR1 was the most expressed VEGF receptor.

No significant financial relationships to disclose.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27963397.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Seizure outcomes were measured by time to second seizure and seizure frequency.

64% had grade 4 astrocytoma.

There was no difference in seizure outcome between the phenytoin and levetiracetam groups when comparing time to second seizure (p = 0.584), second seizure rates (p = 0.462), and average seizures per month (p = 0.776).

When adjusting for age, gender, type of seizure, type of glioma, and dosage using univariate and multivariate models there were no differences between the treatment groups and none of these covariates were statistically significant for explaining the second seizure rates between treatment groups (all p values >0.05).

The incidence of side effects in the levetiracetam group was 5.9% versus 20% in the phenytoin group (p = 0.106).

Additionally, 36.0% of the patients in the phenytoin group had dose adjustments not related to breakthrough seizures compared to only 9.8% in the levetiracetam group (p = 0.010).

CONCLUSIONS: In this study, glioma patients treated with levetiracetam had similar seizure control as patients treated with phenytoin.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: Eligible patients must be ≥18 years with previously treated NPC or other incurable solid tumors; must have measurable disease according to RECIST, ECOG 0-1, and adequate bone marrow, hepatic and renal function.

Majority of stable disease occurred in NPC patients.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27962434.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phase II randomized trial of bortezomib (B) plus irinotecan (I) or B with addition of I at progression in recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN) (E1304): A trial of the Eastern Cooperative Oncology Group.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: 7049 Since the activation-induced cytidine deaminase (AID) enzyme can target non-immunoglobulin (Ig) genes and may even act as a genome-wide mutator, we investigated AID expression in BCR-ABL1-positive ALL and in chronic myeloid leukemia (CML) at the time of progression to blast crisis.

On the 61 de novo adult BCR-ABL1-positive ALL patients (pts), AID mRNA and protein were detected in 36 (59%); their expression correlated with BCR-ABL1 transcript levels and disappeared after treatment with tyrosine kinase inhibitors at the time of remission.

AID expression was also found in lymphoid blast crisis CML (50%), but not in myeloid lineage or in chronic phase CML.

Our findings show that BCR-ABL1-positive ALL cells aberrantly express different isoforms of AID that can act as mutator outside the Ig gene loci in promoting genetic instability in leukemia cells.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27961429.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

57. Reservists seek more support from managers and staff.Nurs Stand; 2008 Oct 22;23(7):12-13

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Reservists seek more support from managers and staff.

: Being a reservist in the Royal Navy is not all about spending weekends on ships or training for combat.

By joining the 1,600 members of the NHS in the UK's reserve forces, nurses can gain key clinical and leadership skills, as well as taking part in life-saving humanitarian missions.

[Email]Email this result itemEmail the results to the following email address: [X] Close

[ISSN] 2047-9018

[ISO-abbreviation] Nurs Stand

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

63. Have a look at the other side of the work/life balance.Nurs Stand; 2007 Aug 01;21(47):32

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Have a look at the other side of the work/life balance.

: Has nursing become the most selfish profession of all?

We constantly moan about night shifts, how staff shortages and deficits are detrimental to quality patient care and nursing intervention, and how this limits our ability to provide the highest standards of nursing.

On the other hand, I cannot help but notice how we seem to forget to look after each other when it comes to shift allocation.

[Email]Email this result itemEmail the results to the following email address: [X] Close

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A phase II study of the tolerability and activity of weekly vincristine sulfate liposomes injection (VSLI) in adults with Philadelphia chromosome-negative (Ph-) acutelymphoblasticleukemia (ALL) in second relapse or progressing following two antileukemia treatment lines.

This population typically has a very low response rate to anti-leukemia therapies.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27961424.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: 7028 Background: The major mechanism underlying imatinib resistance in patients with chronic myeloid leukemia (CML) is clonal expansion of leukemic cells with point mutations in the BCR-ABL tyrosine kinase.

We describe three novel ABL premature termination mutations leading to BCR-ABL truncation in leukemia patients with multidrug (imatinib/nilotinib/dasatinib) resistance.

HL60 cells (a Ph-negative myeloid leukemiacell line) and peripheral blood of healthy subjects were used as negative controls; a human CML cell line (K562) was used as a positive control.

RESULTS: We identified an exon 7 deletion in three CML patients, a 4-nt insertion (908insCAGG) near the exon 5/6 junction in one CML case, and an exon 6 point mutation (997C>T) in one patient with acutelymphoblasticleukemia (ALL).

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27961401.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: Since 2003, in west of France, (Bretagne-Pays de Loire),a network called OMIT(Observatoire des Médicaments et Innovations Thérapeutiques) directed by Regional Health Agencies has been created.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27964334.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Secondary end points included the overall clinical benefit calculated as the sum of complete response (CR), partial response (PR), and stable disease (SD), toxicity, and time to disease progression (TTP).

Nine pts (60%) had visceral and bone disease.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27963335.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Following drug interruption, the pt restarted at 30 mg/m<sup>2</sup>/d and continued for 4 additional cycles before being removed for progressive disease.

Four ovarian cancer and 2 colon cancer pts have achieved decreases ranging from 11-61% in either CA125 or CEA, respectively (4 are associated with stable disease at Cycle 2 by modified RECIST criteria).

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27961327.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The synchronization of dynamic multileaf collimator (DMLC) response with respiratory motion is critical to ensure the accuracy of DMLC-based four dimensional (4D) radiation delivery.

In practice, however, a finite time delay (response time) between the acquisition of tumor position and multileaf collimator response necessitates predictive models of respiratory tumor motion to synchronize radiation delivery.

Predicting a complex process such as respiratory motion introduces geometric errors, which have been reported in several publications.

However, the dosimetric effect of such errors on 4D radiation delivery has not yet been investigated.

Thus, our aim in this work was to quantify the dosimetric effects of geometric error due to prediction under several different conditions.

Dose difference and distance-to-agreement analysis was employed to quantify results.

Based on our data, the dosimetric impact of prediction (a) increased with response time, (b) was larger for 3D radiation therapy as compared with 4D radiation therapy, (c) was relatively insensitive to change in beam energy and beam direction, (d) was greater for IMRT distributions as compared with conformal distributions, (e) was smaller than the dosimetric impact of latency, and (f) was greatest for respiration motion with audio instructions, followed by visual feedback and free breathing.

Geometric errors of prediction that occur during 4D radiation delivery introduce dosimetric errors that are dependent on several factors, such as response time, treatment-delivery type, and beam energy.

Even for relatively small response times of 0.6 s into the future, dosimetric errors due to prediction could approach delivery errors when respiratory motion is not accounted for at all.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: e15087 Background: The EGFR-targeting monoclonal antibody cetuximab has been licensed by the EMEA in combination with chemotherapy for the treatment of 1<sup>st</sup> line metastatic colorectal cancer (mCRC) patients (pts) whose tumors have KRAS wild type status.

The major side effects of cetuximab are cutaneous reactions (approx.

80% of pts.) predominantly consisting of an acne- like rash 60-100%, but also including pruritus, dry skin (35%), desquamation, hypertrichosis and nail disorders (10-40%).

If not properly managed, they have the potential to cause dose reductions and delays, which may in turn impact on treatment efficacy.

The aim of our study was to determine the efficacy of topical vitamin K1 cream in pts with cutaneus side effects caused by cetuximab therapy.

METHODS: Between January 2007 and August 2008, 79 pts with mCRC were treated with weekly cetuximab in combination with chemotherapy.

Topical use of a cream containing urea and 0.1% vitamin K1 was applied when an acne-like rash (NCI CTCAE version 3) appeared .

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Declines in physical function from androgen deprivation therapy (ADT) in men with nonmetastatic prostate cancer: A matched cohort study.

: 9526 Background: Although prolonged use of ADT is hypothesized to adversely affect physical function, few studies have examined this relationship longitudinally using objective measures of physical function.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: 5594 Background: To compare the efficacy of pyridoxine versus placebo in the prevention of palmar-plantar erythrodysesthesia (PPE) and on quality of life (QOL) in patients treated with pegylated liposomal doxorubicin hydrochloride for ovarian, breast, or endometrial cancer.

METHODS: All patients received pegylated liposomal doxorubicin hydrochloride 40 mg/m2 IV q 4 weeks over 1 hour every 28 days for a maximum of 6 cycles.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

CONCLUSIONS: There is no evidence that time lapse from initial imaging to surgical intervention leads to significant changes in tumor size thus allowing patients to complete preoperative workup and planning without significant clinical disease progression.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27961425.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

1 patient had stable disease.

One of the patients with endometrial cancer and extensive intra-abdominal disease who showed rapid tumor regression (≥ 25% decrease at 2 months) developed an entero-colonic fistula, and chose hospice care.

Patients with intra-abdominal disease who experience rapid tumor regression may be at risk for fistula formation.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27961272.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology